A. S. Sigidaev

A. S. Sigidaev

Auto-generated profile, based on publicly available information

A. S. Sigidaev

I.M. Sechenov First Moscow State Medical University (Sechenov University); Tyumen State Medical University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Open access
PDF file
ASA. S. Sigidaev
A. S. Sigidaev
PZP. B. Zotov
P. B. Zotov
ВДВ. А. Дюльдин
В. А. Дюльдин
III. I. Iva
I. I. Iva
KKKonstantin Вадимович Kozlov
Konstantin Вадимович Kozlov
KBK. Bryanskaya-Kasyanenko
K. Bryanskaya-Kasyanenko
   Aim. Evaluation of the effectiveness of the preventive use of the directacting antiviral drug riamilovir in reducing the incidence of COVID-19, as well as its impact on the dynamics of infection spread using mathematical simulation on the example of the Kurgan region population to optimize preventive strategies for epidemiologically significant diseases.   Material and methods. To simulate the spread of COVID-19 in the Kurgan region, the extended SEIR model was used, taking into account the effect of riamilovir on the likelihood of contracting a new coronavirus infection. The numerical solution of the system of differential equations was carried out using the 4th order Runge-Kutta method. The input parameters of the modelwere based on demographic data from the region and the results of a clinical study of riamilovir preventive efficacy against COVID-19 and acute respiratory viral infections. The scenarios under consideration involve 30 % and 50 % of the population taking the drug, which reduced the likelihood of infection by 25.7 % and 40 %, respectively.   Results. Based on mathematical simulation, it has been established that the preventive use of riamilovir by 30% or 50% of the population shifts the peak of the epidemic to a later date, and the maximum number of active cases is significantly reduced compared to the scenario without the drug. The total number of cases is decreasing, which reduces the burden on the healthcare system and improves control over the spread of infection.   Conclusion. Mathematical simulation has shown that the scenario of preventive use of riamilovir on the example of the Kurgan region can significantly reduce the incidence of infections with epidemic potential, reduce the burden on the healthcare system, and slow down the peak of the epidemic.

1 April 2026 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Closed access
AUA. I. Ulyanin
A. I. Ulyanin
EPE. A. Poluektova
E. A. Poluektova
AKAnna Kudryavtseva
Anna Kudryavtseva
Margarita MorozovaMargarita Morozova
Margarita Morozova
OSO. S. Shifrin
O. S. Shifrin
VIVladimir Ivashkin
Vladimir Ivashkin
Aim: to investigate the interrelationships between the severity of clinical symptoms, features of tryptophan metabolism, gut microbiota composition, quality of life, psychoemotional and cognitive status in female patients with functional constipation (FC), and to assess the ability of prucalopride as monotherapy and in combination with a multistrain probiotic to influence these parameters. Materials and methods. The study included 70 female patients with FC, who were randomized into two equal groups: patients of Group FC-P received prucalopride at a dose of 2 mg daily for 8 weeks, and patients of Group FC-PP received prucalopride at a similar dose together with a multi-strain probiotic ( Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus , not less than 1×10 9 CFU of each strain per capsule), 1 capsule 3 times a day for 8 weeks. At baseline, as well as after 2, 4, and 8 weeks, the groups were assessed for the number of defecations per week, stool form (Bristol Stool Scale, BSS), severity of abdominal bloating and abdominal pain against the background of bloating (Visual Analog Scale, VAS), as well as the presence of the need for additional straining, sensation of incomplete and difficult defecation. Before and after treatment, all subjects were assessed for levels of interleukin-1β, cortisol, brain-derived neurotrophic factor, tryptophan, kynurenine, kynurenic acid, serum and platelet serotonin, psychoemotional status (Spielberger — Hanin test, STAI), Hamilton Depression Rating Scale (HDRS), Four-Dimensional Symptom Questionnaire (4DSQ)), cognitive status (Brief Assessment of Cognition in Schizophrenia, BACS), quality of life (SF-36), and gut microbiota composition in stool samples (16S rRNA sequencing). Results. The study was completed by 34 patients in Group FC-P and 30 patients in Group FC-PP. Abdominal bloating directly correlated with the severity of somatization ( r = 0.25; p < 0.005) and inversely — with cortisol levels ( r = –0.29; p < 0.05). The severity of abdominal pain directly correlated with the levels of state and trait anxiety (STAI), distress, anxiety, and somatization (4DSQ) ( r = 0.32, p < 0.05; r = 0.28, p < 0.05; r = 0.31, p < 0.05; r = 0.26, p < 0.05; r = 0.35, p < 0.005, respectively) and inversely — with the indicators of vitality, emotional role functioning, and mental health (SF-36) ( r = –0.28, p < 0.05; r = –0.32, p < 0.01; r = –0.30, p < 0.05, respectively). Stool form type inversely correlated with the level of kynurenine ( r = –0.27; p < 0.05) and kynurenic acid ( r = –0.26; p < 0.05). The sensation of incomplete evacuation correlated with the severity of depression according to HDRS ( r = 0.27, p < 0.05) and state anxiety ( r = 0.25; p < 0.05), while the sensation of difficult evacuation directly correlated with the level of interleukin-1β ( r = 0.25; p < 0.05) and distress ( r = 0.27; p < 0.05) and inversely with the ratio of plasma serotonin to kynurenine ( r = –0.27; p < 0.05). The number of defecations per week and the presence of the need for additional straining did not show statistically significant correlations with any of the variables. The age of the subjects, duration of the disease, and cognitive indicators did not demonstrate a reliable correlation with the severity of FC symptoms. When assessing the gut microbiota composition, various correlations with FC symptoms were identified, the most significant of which was a direct correlation between the level of bacteria from the Ruminococcaceae family and the severity of abdominal bloating ( r = 0.39; p < 0.05). After randomization, the formed groups did not differ significantly in the assessed clinical, laboratory, and psychometric parameters, quality of life, age, and disease duration ( p > 0.05). During treatment, both groups showed significant improvement in all clinical parameters; however, Group FC-P showed a more pronounced reduction in abdominal pain ( p < 0.005) and sensation of incomplete evacuation ( p < 0.05). Only in Group FC-P was a significant improvement in cognitive function observed, with the total score and the results of the BACS subtests “Semantic and Phonemic Verbal Fluency”, “Digit Sequencing”, and “Tower of London” being significantly higher than in Group FC-PP ( p < 0.0001, p < 0.05, p < 0.05, and p < 0.0001, respectively). Quality of life, on the contrary, was significantly higher in Group FC-PP due to the indicators “Vitality” ( p < 0.05), “Emotional Role Functioning” ( p < 0.001), and “Mental Health” ( p < 0.05). A key difference in gut microbiota composition between the groups at the end of treatment was a change in the abundance of representatives of the order Lactobacillales , specifically the family Streptococcaceae , which increased in Group FC-P and decreased in Group FC-PP ( p < 0.05). In Group FC-PP, the number of representatives of the Ruminococcaceae family ( p < 0.05) and other bacteria capable of synthesizing short-chain fatty acids also increased significantly. No adverse events during therapy were reported in either group throughout the entire observation period. Conclusion. Disruption of the components of the “microbiota — gut — brain” axis in FC is closely associated with the symptoms of the disease. The efficacy of prucalopride as monotherapy and in combination with a multistrain probiotic regarding the symptoms of FC develops through influence on components of the “microbiota — gut — brain” axis not directly related to the pathogenesis of FC, while these approaches have divergent effects on cognitive function, quality of life, and the abundance of individual representatives of the phylum Firmicutes ( Bacillota ).